Objective: To investigate the influence of qigong on late positive potential, which was elicited by affective pictures.Methods: College students who met the inclusion criteria were enrolled and randomly allocated to the qigong group, which received a four-week training (n=41) or the control group (n=41). All participants were assessed before and after the training for event-related potential, which was elicited by negative, neutral, and positive pictures. Electrodes at the centerline position of the frontal area (FCz), parietal area (Pz), and occipital area (Oz) were analyzed. Results: Negative, neutral, and positive pictures demonstrated statistically significant differences on FCz (P<.001), Pz (P<.001), and Oz (P<.001). The interaction between the group factor and time factor was statistically significant on Pz (P =.028). The pairwise comparison of Pz on the time factor and group factor showed that the amplitudes of the qigong group after training were smaller than before (P<.001), and the amplitudes of the control group were not statistically significant (P=.355). Conclusion: Our results supported the conclusion that qigong practices could affect the emotional regulation of college students. Qigong exercise weakens the emotional regulation of late positive po-tential, which is sensitive to top-down affective modulation. The findings imply that the regulating effect of qigong on emotions may be part of the reason why it is effective in reducing depression and anxiety symptoms.

BACKGROUND: The new emerging avian influenza A H7N9 virus, causing severe human infection with a mortality rate of around 41%. This study aims to provide a novel treatment option for the prevention and control of H7N9. METHODS: H7 hemagglutinin (HA)-specific B cells were isolated from peripheral blood plasma cells of the patients previously infected by H7N9 in Jiangsu Province, China. The human monoclonal antibodies (mAbs) were generated by amplification and cloning of these HA-specific B cells. First, all human mAbs were screened for binding activity by enzyme-linked immunosorbent assay. Then, those mAbs, exhibiting potent affinity to recognize H7 HAs were further evaluated by hemagglutination-inhibiting (HAI) and microneutralization in vitro assays. Finally, the lead mAb candidate was selected and tested against the lethal challenge of the H7N9 virus using murine models. RESULTS: The mAb 6-137 was able to recognize a panel of H7 HAs with high affinity but not HA of other subtypes, including H1N1 and H3N2. The mAb 6-137 can efficiently inhibit the HA activity in the inactivated H7N9 virus and neutralize 100 tissue culture infectious dose 50 (TCID50) of H7N9 virus (influenza A/Nanjing/1/2013) in vitro, with neutralizing activity as low as 78 ng/mL. In addition, the mAb 6-137 protected the mice against the lethal challenge of H7N9 prophylactically and therapeutically. CONCLUSION The mAb 6-137 could be an effective antibody as a prophylactic or therapeutic biological treatment for the H7N9 exposure or infection.
Animals ; Antibodies, Monoclonal/therapeutic use* ; Antibodies, Neutralizing/therapeutic use* ; Antibodies, Viral ; Hemagglutinins ; Humans ; Influenza A Virus, H1N1 Subtype ; Influenza A Virus, H3N2 Subtype ; Influenza A Virus, H7N9 Subtype ; Influenza Vaccines ; Influenza in Birds ; Influenza, Human/prevention & control* ; Mice